Pricing And Reimbursement Overview

Patented drugs prices in Canada have to be approved by 19 bodies, including 17 provincial ones. The Common Drug Review and the federal Patented Medicines Review Board (PMRB) are the major governmental bodies in this process. The protracted and complex approvals process can hinder access to new and innovative medicines, and streamlining will ultimately be necessary. However, we believe that the decentralised nature of the pricing strategy is unlikely to change.

To read the full article, please choose one of the following options: